Company intelligence / Profile preview
Abzyme Therapeutics
Pottstown/Royersford*, PA, United Statesabzymetx.com ↗
- Ownership
- Private
- Employees
- ~8
- Development stage
- Other
01
Overview
Abzyme Therapeutics develops modular single-domain VHH antibody fragments using proprietary yeast display-based platforms. The company’s lead programs target retinal neovascular diseases with multi-specific long-lasting antibodies that inhibit both VEGF and other angiogenic factors. Most pipeline assets are in preclinical development across oncology and immunotherapy indications. The company claims over sixty proprietary or partnered programs spanning infectious disease, immuno-oncology, ophthalmology, inflammation and CNS disorders. No clinical results have been published to date.
- Therapeutic areas
- OphthalmologyImmunologyOncologyNeurologyInfectious Diseases
- Modalities
- Single-domain VHH antibody fragments (camelid antibodies)Monoclonal antibodies (mAbs)Bispecific T-cell engagers (BiTEs)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Abzyme Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Abzyme Therapeutics.